MedTrace Logo

Randomized Trial Comparing 3 Routes of Delivering Lorazepam to Children.

NCT00343096 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2012-07-10

No results posted yet for this study

Summary

This study aims to address the hypothesis that Lorazepam (an anticonvulsant) is as effective when given via the intranasal or buccal route as the intravenous route in terminating convulsions in children.

Conditions

  • Status Epilepticus
  • Convulsions

Interventions

DRUG

Lorazepam

All doses 0.1mg/kg once, repeat after 10 minutes x1

Sponsors & Collaborators

  • Kamuzu University of Health Sciences

    lead OTHER

Principal Investigators

  • Elizabeth Molyneux · College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
2 Months
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • Malawi

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00343096 on ClinicalTrials.gov